Rate My Professor George Vassiliou

Vassiliou's research specializes in the pathogenesis of acute myeloid leukaemia (AML) and related myeloid malignancies, focusing on cell-autonomous and non-cell-autonomous processes transforming normal haemopoietic stem cells into leukaemic stem cells. He investigates genetic vulnerabilities through CRISPR screens, develops bespoke mouse models of somatic mutations, and studies clonal haematopoiesis in healthy individuals to predict leukaemic progression, enabling early detection and prevention strategies. Key contributions include leading the Specialized Center of Research into Myeloid Cancer Prevention and spearheading a £4m project for a clinical platform in blood cancer prevention. Notable publications encompass 'Prediction of acute myeloid leukaemia risk in healthy individuals' (Nature, 2018), 'Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis' (Nature, 2025), 'Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis' (Nature Genetics, 2025), 'Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML' (Blood, 2025), 'Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis' (Nature Genetics, 2022), and 'Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice' (Nature Genetics, 2011). His work advances therapeutic approaches for AML, myelodysplastic syndromes, and related conditions, with applications in genetic screens and epidemiological studies.